IMCR News and Press, Immunocore Holdings plc From 10/21/23

Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01 positive patients with previously untreated metastatic uveal melanoma (OXFORDSHIRE...

Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a late-breaking abstract in a mini oral session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn....

2023-09-01 08:00:00 ET Summary Aura Biosciences is developing virus-like particles derived from HPV to target specific modifications on tumor cells. Their first product candidate, BelSar, has shown potential in halting tumor growth in uveal melanoma, but not shrinking tumors. ...

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...

2023-08-14 15:22:00 ET Summary Two new Breakout Stocks for Week 33 curated by the MDA model for 10% short-term upside along with one Dow pick. Last week two of four picks gained over the 10% mark in less than a week with peak gains in EHTH +12.3% and ATEX +15.4% still near highs. ...

2023-08-10 13:26:06 ET Immunocore Holdings plc (IMCR) Q2 2023 Earnings Conference Call August 10, 2023, 08:00 AM ET Company Participants Clayton Robertson - Head of IR Bahija Jallal - CEO and Director Brian Di Donato - CFO and Head of Strategy Ralph Torbay - ...

2023-08-10 07:24:17 ET Immunocore press release ( NASDAQ: IMCR ): Q2 GAAP EPS of -$0.37 beats by $0.06 . Revenue of $60.7M (+49% Y/Y) beats by $1.94M . For further details see: Immunocore GAAP EPS of -$0.37 beats by $0.06, revenue of $60.7M beats by $1.94M

Immunocore Reports Second Quarter 202 3 Financial Results and Provides Business Update KIMMTRAK net revenues of £ 45 . 5 million ($ 57.8 million) in 2 Q 2023 ; new launches in Italy , Austria , Finlan...

Immunocore to report second quarter 2023 financial results and host call on August 10, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 August 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the devel...

2023-07-31 14:43:42 ET Summary Two new Breakout Stocks for Week 31 curated by the MDA model for 10% short-term upside and additional model selections. This week two of four picks gained over 10% in less than a week with peak gains in CLLS +16.8% AUTL+15.5% but the portfolio failed...